Team News Riveting
Mumbai, December 29
J B Chemicals and Pharmaceuticals Limited (JBCPL), one of the fastest growing pharmaceutical companies in India is set to launch Molnupiravir 200 mg for the Indian market.
Marketed under the brand name Molunamax, it will soon be available all across the country in the next month for the treatment of mild COVID-19. Recently Molnupiravir, received U.S. FDA, Emergency Use Authorization (EUA) for the Treatment of Mild to Moderate COVID-19. Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made, and within five days of symptom onset.
In India, the CDSCO has recently recommended for grant of permission to manufacture and market Molnupiravir 200 mg capsule for restricted use under emergency situation in the country for treatment of patients above the age of 18 years, diagnosed COVID-19 positive, with SpO2 > 93 per cent and those who have a high risk of progression of the disease.
The recommended dose for Molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for five days, with or without food. Completion of the full five-day treatment course is important to maximize viral clearance and may help in minimizing the transmission of SARS-CoV-2.
J.B. Chemicals & Pharmaceuticals Limited is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 brands in the country. The company exports its finished formulations to over 30 countries including the USA.
Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges.
